- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT00617838
Celiac Disease Prevention
Prevention of Celiac Disease in Children at Genetic Risk - Optimized Introduction of Gluten and Follow-up of Immunization
Celiac disease is an autoimmune disease induced by wheat gluten. Destruction of epithelial cells and microvilli on gut mucosa is causing a "flat mucosa" and an absorption defect. The diagnosis is based on typical microscopical finding in biopsy specimens but serum antibodies to tissue transglutaminase and certain gliadin peptides are strongly associated with the pathology. Severe diarrhoea associated with growth disturbance in infancy was historically characterising the disease but is nowadays rare. Clinically more mild forms including silent disease are very common. Studies based on antibody screening and biopsies done in autoantibody positive subjects have confirmed a frequency of about 1-2% in adult population. Undiagnosed disease is associated with deficiencies of nutrients and vitamins leading to various chronic symptoms like anaemia, osteoporosis and general fatigue. It has also been recently found that undiagnosed celiac disease may be associated with general underachievement in society probably associated with common psychological symptoms like fatigue and depression during the adolescence. The disease is treated by complete elimination of wheat, rye and barley in the diet, which is laborious and causing considerable extra costs in nutrition.
Much progress has been recently made in understanding of the genetic background and immune markers associated with the disease as well as in understanding those patterns of gluten introduction in infancy, which might be connected to a high disease risk. Our aim in this study is in the first phase to identify children at high genetic risk (around 10%) and in a follow-up study to define:
- Are the age, dose of gluten and presence of simultaneous breast feeding at the introduction of gluten associated with the risk of celiac disease?
- Is it possible to decrease the frequency of celiac disease by nutritional counselling?
- Is it possible to predict development of celiac disease by immunological tests before the development of mucosal lesion
If we can confirm, that optimising the conditions at the introduction of wheat gluten in infancy diet significantly reduces the disease incidence, will this have an important effect on the nutritional recommendations concerning the diet in infancy. Combining genetic screening and immunological tests might also offer a way to reduce the frequency of celiac disease and help in early diagnosis and organisation of an adequate treatment
Studieoversigt
Undersøgelsestype
Tilmelding (Faktiske)
Fase
- Ikke anvendelig
Kontakter og lokationer
Studiesteder
-
-
-
Kuopio, Finland, FIN-70211
- Kuopio University Hospital
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
- Presence of HLA-risk alleles DQA1*05 and DQB1*02
Exclusion Criteria:
- Lack of these HLA risk alleles
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Forebyggelse
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Enkelt
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
|---|---|
|
Aktiv komparator: 1
Optimization of gluten introduction by nutritional councelling
|
Optimization of gluten introduction by nutritional counselling
|
|
Ingen indgriben: 2
No specific nutritional councelling.
Follow-up of gluten introduction
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Tidsramme |
|---|---|
|
development of transglutaminase antibodies
Tidsramme: 2-4 year age
|
2-4 year age
|
Sekundære resultatmål
Resultatmål |
Tidsramme |
|---|---|
|
gliadin peptide antibodies
Tidsramme: 2-4 years
|
2-4 years
|
|
mucosal biopsy in TGA positive childre
Tidsramme: 2-4 years
|
2-4 years
|
Samarbejdspartnere og efterforskere
Sponsor
Samarbejdspartnere
Efterforskere
- Ledende efterforsker: Jorma Ilonen, MD, University of Eastern Finland
Datoer for undersøgelser
Studer store datoer
Studiestart
Primær færdiggørelse (Forventet)
Studieafslutning (Forventet)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Skøn)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Skøn)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
- KUH5021612
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .
Kliniske forsøg med Optimal gluten introduction
-
Cambridge Health AllianceSpaulding Rehabilitation Hospital; Korea Advanced Institute of Science...Afsluttet
-
Royal North Shore HospitalAktiv, ikke rekrutterende
-
Karolinska InstitutetSt. Claraspital AGTrukket tilbageDiabetisk nyresygdomSverige, Schweiz
-
University of IowaNational Institute on Aging (NIA)Afsluttet
-
NTK Enterprises, Inc.Afsluttet
-
Uptake Medical Technology, Inc.MedPass InternationalAfsluttet
-
Aeris TherapeuticsAfsluttetLungeemfysemForenede Stater, Spanien, Frankrig, Israel, Holland, Grækenland, Italien
-
China National Center for Cardiovascular DiseasesAfsluttetKoronararteriesygdomKina
-
Bispebjerg HospitalAktiv, ikke rekrutterende